Relistor for treating OIC

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

Anne Chiang, MD

October 20th 2025

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Caroline Seymour

CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Grade 3 or 4 AEs were experienced by 42.9% of patients who received cisplatin plus radiation compared with 15.3% of patients who received radiation alone.

An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer

Grade 3 or 4 AEs were experienced by 42.9% of patients who received cisplatin plus radiation compared with 15.3% of patients who received radiation alone.

Related Content

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

Anne Chiang, MD

October 20th 2025

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.

Caroline Seymour

CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.